Necrostatin-5
Based on 1 publication(s) in Google Scholar
Necrostatin-5 (Nec-5) is a potent necroptosis inhibitor with an EC50 value of 0.24 µM. Necrostatin-5 also is a RIP1 inhibitor. Necrostatin-5 shows cardioprotective effects.
For research use only. We do not sell to patients.
- Purity: 99.40%
- CAS No.: 337349-54-9
- Formula: C19H17N3O2S2
- Molecular Weight:383.49
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Kinase Inhibitor Library
HY-L009
-
NF-κB Signaling Compound Library
HY-L014
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) Necrostatin-5
More
Biological Activity
|
RIPK1 |
necroptosis 0.24 μM (EC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Jurkat | EC50 |
0.24 μM
Compound: Nec-15; N13
|
Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 38199165] |
| Jurkat | EC50 |
0.24 μM
Compound: Nec-5
|
Inhibition of TNF-alpha-induced necroptosis in FADD-deficient Jurkat T cells
Inhibition of TNF-alpha-induced necroptosis in FADD-deficient Jurkat T cells
|
[PMID: 17270434] |
| Jurkat | EC50 |
240 nM
Compound: 3
|
Inhibition of cellular necroptosis in TNFalpha treated FADD deficient human Jurkat cells
Inhibition of cellular necroptosis in TNFalpha treated FADD deficient human Jurkat cells
|
[PMID: 18408713] |
Necrostatin-5 (1, 5, 10, 50, 100 µM) inhibits LDH release in a dose-dependent mnner[3].
Necrostatin-5 (100 µM) protects MH-S cells against challenge with S. aureus, Listeria monocytogenes, S. pneumoniae, uropathogenic Escherichia coli (UPEC), and protectes against pneumolysin-induced death[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:200-300 g, male Wistar rats[2]
-
Dosage:2.46 mg/kg
-
Administration:I.p.; 60 min before experiment
-
Result:Reduced the infarction zone caused by 30-min global ischemia and 120-min reperfusion.
Chemical Information
-
CAS No. 337349-54-9
-
Appearance Solid
-
Molecular Weight 383.49
-
Formula C19H17N3O2S2
-
Color White to off-white
-
SMILES
O=C(N1C2=CC=C(C=C2)OC)C3=C(N=C1SCC#N)SC4=C3CCCC4
-
Synonyms
Nec-5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Biochem Biophys Res Commun
Engineered MAP30ER: A plant toxin-derived platform for EGFR-Targeted delivery of protein and chemotherapeutic payloads. [Abstract]2025 Jun 10:776:152184. PMID: 40517671
Solvent & Solubility
DMSO : 5 mg/mL (13.04 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wang K, et al. Structure-activity relationship analysis of a novel necroptosis inhibitor, Necrostatin-5. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1455-65. [Content Brief]
[2]. Dmitriev YV, et al. Study of cardioprotective effects of necroptosis inhibitors on isolated rat heart subjected to global ischemia-reperfusion. Bull Exp Biol Med. 2013 Jun;155(2):245-8. [Content Brief]
[3]. González-Juarbe N, et al. Pore-Forming Toxins Induce Macrophage Necroptosis during Acute Bacterial Pneumonia. PLoS Pathog. 2015 Dec 11;11(12):e1005337. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6076 mL | 13.0381 mL | 26.0763 mL | 65.1907 mL |
| 5 mM | 0.5215 mL | 2.6076 mL | 5.2153 mL | 13.0381 mL | |
| 10 mM | 0.2608 mL | 1.3038 mL | 2.6076 mL | 6.5191 mL |
Powered by Bioz